Autolus Therapeutics PLC, a prominent player in the biotechnology sector, has announced its intention to release its second-quarter 2026 financial results and operational highlights. This announcement is set to occur ahead of the opening of U.S. markets on Tuesday, August 11, 2026. The company will host a conference call and webcast to discuss these forthcoming results and provide a general business update.
Based in London, United Kingdom, Autolus Therapeutics PLC is a bio-pharmaceutical company specializing in the development of cell therapies aimed at treating cancer. As a commercial-stage biopharmaceutical entity, Autolus is actively involved in the health care industry, operating nationwide within the United Kingdom. The company is listed on the Nasdaq stock exchange, having made its Initial Public Offering (IPO) on June 22nd, 2018.
Autolus is renowned for its innovative approach to developing next-generation programmed T-cell therapies, targeting both cancer and autoimmune diseases. The company currently markets AUCATZYL®, a notable product in its portfolio. Additionally, Autolus maintains a robust pipeline of candidates that focus on hematological malignancies, solid tumors, and autoimmune conditions.
In recent trading sessions, Autolus’s share price has aligned with broader biotech gains, reflecting the dynamic nature of the sector. Analysts at HC Wainwright & Co. have reiterated their coverage of Autolus’s stock, maintaining their price target. This endorsement underscores the company’s strategic positioning and potential within the biotechnology landscape.
As of August 4, 2026, Autolus’s close price stood at $1.9, with a 52-week high of $2.52 recorded on August 10, 2025, and a 52-week low of $1.175 on March 26, 2026. The company’s market capitalization is valued at approximately $518,979,424 USD. Despite a negative price-to-earnings ratio of -1.4, Autolus continues to focus on advancing its therapeutic offerings and expanding its impact in the biotechnology field.
For more detailed information about Autolus Therapeutics PLC’s activities and offerings, interested parties are encouraged to visit their official website at www.autolus.com .
